NewsSource: EClinCloud

Invitation | EClinCloud invites you to the 2024 China (Ningbo) Biopharmaceutical Industry Development Conference

2 min readEClinCloud Editorial Team
Article illustration

Source: EClinCloud. Author: EClinCloud.

Article illustration

Click the image above to view the full conference agenda


The 3rd China (Ningbo) Biopharmaceutical Industry Development Conference will be held from November 22 to 23 in Ningbo Qianwan New Area. The conference will focus on themes including R&D innovation and international cooperation: in R&D innovation, it will pay particular attention to areas such as metabolic and obesity-related diseases and immune system diseases; in business cooperation, it will feature in-depth discussions on key topics such as innovative drug investment and financing and the NewCo model.


During the conference, the EClinCloud team will host an exhibition booth on site to share achievements in supporting clinical research with digital and intelligent technologies with industry colleagues, and we look forward to welcoming you for discussions.


EClinCloud Booth Location:

We look forward to welcoming you for discussions!

Article illustration


Visit our booth for an interactive prize draw

100% win rate!

Event gifts are limited and available on a first-come, first-served basis
Article illustration



EClinCloud looks forward to seeing you there


Conference Details

Conference Dates: November 22–23, 2024

Conference Venue: Hyatt Regency Ningbo Hangzhou Bay

*Click "Read Original" at the end of the article to view the full conference agenda and register




About EClinCloud

EClinCloud is a technology company focused on clinical R&D. It provides an integrated, interconnected all-in-one clinical trial cloud platform (including solutions such as scale design, scale copyright management, linguistic validation, rater training, and data quality analysis across technology products and solutions including eCOA, CTMS, eTMF, EDC, RTSM, and RM) as well as clinical trial endpoint assessment technologies across therapeutic areas (including central nervous system, ophthalmology, and others). By combining cutting-edge technology with life sciences data, it builds a globally leading, "patient-centric" SaaS cloud platform for clinical evidence support to help domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs and devices, and benefit countless patients.







Article illustration

Read original WeChat article

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.